SLC5A2 and metabolic dysfunction-associated steatotic liver disease: By integrating TyG-BMI into routine diabetes care (e.g., during annual screenings), clinicians could prioritize intensive monitoring (e.g., hepatic ultrasound for NAFLD, DEXA scans for osteoporosis) or targeted interventions (e.g., SGLT2 inhibitors for cardiorenal protection) for high-risk subgroups, optimizing resource allocation in resource-constrained settings.